Goldman Sachs Initiates Elanco at Buy and Zoetis at Neutral
Goldman Sachs initiated coverage of Elanco Animal Health at Buy with a $32 target and Zoetis at Neutral with a $74 target, per Benzinga data via TradingView.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Goldman Sachs analysts began coverage of two animal health companies on October 16. Elanco Animal Health received a Buy rating with a $32 price target per share. Zoetis was rated Neutral with a $74 target.
The information was published by TradingView, citing Benzinga's ratings feed. Both entries are initial coverage rather than revisions of earlier forecasts.
why it matters
Initial ratings like these usually shift sentiment in individual stocks rather than the broader market. For animal health names they serve as a valuation reference point, but they do not by themselves set the direction of prices.
tags
instruments
sources
- Elanco Animal Health Price Target Announced at $32.00/Share by Goldman Sachs — ru.tradingview.com, 16 October 2026 at 20:35 UTC
- Zoetis Price Target Announced at $74.00/Share by Goldman Sachs — ru.tradingview.com, 16 October 2026 at 20:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗